XML 16 R4.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)        
Net Revenue $ 6,277,133 $ 2,967,183 $ 11,286,569 $ 6,491,514
Cost of goods sold 536,405 348,675 1,010,838 678,863
Gross profit 5,740,728 2,618,508 10,275,731 5,812,651
Operating expenses        
Selling, general and administrative expenses 6,562,144 3,582,511 11,971,874 8,514,662
Research and development 103,981 41,516 222,193 45,903
Depreciation and amortization 100,807 74,221 191,398 127,726
Total operating expenses 6,766,932 3,698,248 12,385,465 8,688,291
Operating loss (1,026,204) (1,079,740) (2,109,734) (2,875,640)
Other expense        
Other expense 0 (48,716) 0 (85,474)
Interest expense 0 (1,101) (711) (9,455)
Share of losses from equity method investment (179,769) 0 (278,904) 0
Total other expense (179,769) (49,817) (279,615) (94,929)
Net loss (1,205,973) (1,129,557) (2,389,349) (2,970,569)
Less: Net loss attributable to noncontrolling interest (34,481) (3,793) (36,113) (7,848)
Net loss attributable to Sanara MedTech common shareholders $ (1,171,492) $ (1,125,764) $ (2,353,236) $ (2,962,721)
Net loss per share of common stock, basic and diluted $ (0.16) $ (0.18) $ (0.33) $ (0.54)
Weighted average number of common shares outstanding, basic and diluted 7,496,604 6,203,577 7,158,503 5,477,759